comparemela.com
Home
Live Updates
Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer : comparemela.com
Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer
Trastuzumab deruxtecan improved PFS vs chemotherapy in pretreated, HR-positive, HER2-low or -ultralow metastatic breast cancer.
Related Keywords
Connecticut ,
United States ,
New Haven ,
Daiichi Sankyo ,
Daichii Sankyo ,
Roche Genentech ,
Ian Krop ,
Bristol Myers Squibb ,
Glaxosmithkline ,
European Society Of Breast Cancer Specialists ,
Pfizer ,
Guardant Health ,
Samsung ,
Clinical Trials Office ,
Novartis ,
Clinical Sciences At Yale Cancer Center ,
Boehringer Ingelheim ,
Gilead Sciences ,
Astrazeneca ,
Foundation Medicine ,
Clinical Sciences ,
Yale Cancer Center ,
European Society ,
Breast Cancer Specialists ,
Ellipses Pharma ,
Blueprint Medicines ,
Exact Sciences ,
Hengrui Therapeutics ,
comparemela.com © 2020. All Rights Reserved.